UniProt Q96SB4 · PDB · AlphaFold · Substrate: RS peptide · Clone: full lengthhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Alectinib | 99.6% | 0.4% | 95.49 | 0.651 |
| 2 | Ceritinib | 50.5% | 49.5% | 95.44 | 0.618 |
| 3 | Abrocitinib | 47.9% | 52.1% | 99.50 | 0.581 |
| 4 | Defactinib | 35.7% | 64.3% | 92.68 | 0.450 |
| 5 | Brigatinib | 24.3% | 75.7% | 82.96 | 0.513 |
| 6 | Gilteritinib | 22.9% | 77.1% | 88.97 | 0.506 |
| 7 | Repotrectinib | 22.3% | 77.7% | 84.21 | 0.608 |
| 8 | Midostaurin | 21.8% | 78.2% | 78.64 | 0.500 |
| 9 | Lorlatinib | 19.1% | 80.9% | 97.24 | 0.694 |
| 10 | Ponatinib | 14.6% | 85.4% | 78.23 | 0.534 |
| 11 | Mitapivat | 14.4% | 85.6% | 100.00 | 0.625 |
| 12 | Crizotinib | 14.2% | 85.8% | 91.39 | 0.581 |
| 13 | Lapatinib | 13.2% | 86.8% | 99.25 | 0.616 |
| 14 | Tucatinib | 11.9% | 88.1% | 99.75 | 0.652 |
| 15 | Avapritinib | 11.8% | 88.2% | 97.73 | 0.644 |
| 16 | Ripretinib | 11.7% | 88.3% | 92.95 | 0.674 |
| 17 | Pralsetinib | 10.3% | 89.7% | 93.43 | 0.643 |
| 18 | Larotrectinib | 9.7% | 90.3% | 99.25 | 0.710 |
| 19 | Rabusertib | 9.5% | 90.5% | 98.74 | 0.687 |
| 20 | Acalabrutinib | 9.4% | 90.6% | 99.50 | 0.670 |
Paralog block
SRPK1, SRPK2
EMT expression
- Mesenchymal log2(TPM+1): 4.94
- Epithelial log2(TPM+1): 5.31
- Fold change: -0.37
- Status: No significant change
High-confidence drugs
- Alectinib — inh 99.6% · KISS 42.26
- Abrocitinib — inh 47.9% · KISS -2.23
- Ceritinib — inh 50.5% · KISS -8.28
Selectivity landscape vs inhibition on SRPK1
Each point is one of the 92 approved drugs; color = inhibition % on SRPK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…